Recombinant Human IGFBP3/IBP3 Protein (His Tag)
Recombinant Human IGFBP3/IBP3 Protein (His Tag) supplied by Elabscience with collaborator-provided technical specifications. Read more ›
["1. Immobilized human IGF2 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 18 ng/mL. 2. Immobilized human IGF1 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 24 ng/mL. 3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K. P. et al. (1988) Cancer Research 48:4083. ). The ED50 for this effect is typically 0.02-0.2 μg/mL in the presence of 14 ng/mL human IGFII. ,40-45 kDa"]Product Description
IGFBP3/IBP3 is the stated recombinant protein target for this Elabscience product. The listing uses collaborator-supplied specifications to support research-use-only protein selection through ABMIUM.
Protein profile: reactive species/source: Human; expression system: HEK293 Cells; physical form: Lyophilized from sterile PBS, pH 7.4<br/>Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.<br/>Please refer to the specific buffer information in the printed manual.; tag: Human ,IGFBP3/IBP3 ,Recombinant Proteins; predicted molecular weight: 31.0 kDa.
Quality and formulation: purity: > 85 % as determined by reducing SDS-PAGE.; endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method..
Functional evidence: activity: 1. Immobilized human IGF2 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC<sub>50</sub> of biotinylated Human His-IGFBP3 is 18 ng/mL. 2. Immobilized human IGF1 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC<sub>50</sub> of biotinylated Human His-IGFBP3 is 24 ng/mL. 3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K. P. et al. (1988) Cancer Research 48:4083. ). The ED<sub>50</sub> for this effect is typically 0.02-0.2 μg/mL in the presence of 14 ng/mL human IGFII.. In the ABMIUM matrix, collaborator-supplied functional evidence is marked C; unsupported application columns remain N.
Sequence coverage: 31.0 kDa.
Database references: UniProt: NP_000589.2 | NCBI Gene: 3486 | Gene symbol: IGFBP3/IBP3.
Research Use Only.
Key Facts
| Target | IGFBP3/IBP3 |
| Also known as | BP-53, IBP3, IGFBP3 |
| Species reactivity | Human |
| Purity | > 85 % as determined by reducing SDS-PAGE. |
| Form / buffer | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Shelf life | 12 months |
| Research area | Signal Transduction, Cell biology, Cardiovascular, Cancer, metabolism, |
| BIOACTIVITY | BINDING | CELL-BASED | IN VIVO | ELISA CAPTURE | |
|---|---|---|---|---|---|
| Human |
Specifications
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Storage & Stability
Compliance & Certifications
Manufactured under ISO 9001:2015 quality management standards.
Manufactured under ISO 14001:2015 quality management standards.
Manufactured under ISO 45001:2018 quality management standards.
Not intended for diagnostic or therapeutic use.
Substance does not appear on the SVHC candidate list.